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BiomarkersSchizophrenia has been associated with central nervous system and peripheral immune system imbalances.
However, most studies have not yielded conclusive results due to limitations such as small sample size, dissim-
ilarities in the clinical status of patients and the high variability of cytokine levels within the normal human pop-
ulation. Here, we have attempted to account for these limitations by carrying out standardised multiplex
immunoassay analyses of 9 cytokines in serum from180 antipsychotic-naïvefirst-episode schizophrenia patients
and 350 matched controls across 5 clinical cohorts. All subjects were matched for potential confounding factors
including age, gender, smoking and body mass index.We found that the levels of interleukin (IL)-1RA, IL-10 and
IL-15were increased significantly in patients across the cohorts.We also found that the levels of IL-1RA and IL-10
were decreased in 32 patients who had been followed up and treated for 6 weeks with atypical antipsychotics.
Interestingly, we found that the changes in IL-10 levels were significantly correlated with the improvements in
negative, general and total symptom scores. These results indicate that mixed pro- and anti-inflammatory re-
sponses may be altered in first onset patients, suggesting a role in the aetiology of schizophrenia. The finding
that only the anti-inflammatory cytokine IL-10 responded to treatment in parallel with symptom improvement
suggests that this could be used as a potential treatment response biomarker in future studies of schizophrenia.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Schizophrenia is a severe psychiatric disorder with a complex and
heterogeneous aetiology. Previous studies have indicated that alter-
ations in immune system function may be involved in the disease pro-
cess in at least a subgroup of patients (Drexhage et al., 2010; Muller
and Schwarz, 2010). Well-established risk factors for schizophrenia in-
clude auto-immune and allergic diseases (Eaton et al., 2006; Pedersen
et al., 2012), genetic variations in the human leukocyte antigen (HLA)-
region on chromosome 6 (Stefansson et al., 2009), winter and spring
birth seasons (Davies et al., 2003), and perinatal and childhood infec-
tions (Dalman et al., 2008). Other evidence for immune systemdysfunc-
tion in schizophrenia include the finding of activated microglia in thengineering and Biotechnology,
idge, UK. Tel.:+44 1223334151.
tte), jt455@cam.ac.uk
es.cam.ac.uk (P.C. Guest),
(R.S. Kahn), sb209@cam.ac.ukbrain (van Berckel et al., 2008; Doorduin et al., 2009) and altered levels
of cytokines and other inflammatory markers in the cerebrospinal fluid
and blood (Potvin et al., 2008;Miller et al., 2011). Thesefindings suggest
that the immune system may constitute a potential target for novel
treatment approaches in schizophrenia. Indeed, recent clinical trials
have shown that augmentation of antipsychotic treatment with non-
steroidal anti-inflammatory drugs (NSAIDs) improves symptoms in
schizophrenia patients (Sommer et al., 2011).
The finding that immune alterations in schizophrenia have been
found within the brain and cerebrospinal fluid, as well as in peripheral
systems such as blood serum and leukocytes, suggests that systemic in-
flammatory processes are involved in schizophrenia pathogenesis
(Maino et al., 2007; Potvin et al., 2008; Chan et al., 2011; Drexhage
et al., 2011a,b; Miller et al., 2011; Schwarz et al., 2012). A previously
published meta-analysis of 14 studies on serum cytokine alterations in
first-episode schizophrenia patients (N between 4 and 83) found in-
creased levels of interleukin (IL)-1β, IL-6, IL-12, tumour necrosis factor
(TNF)-α, transforming growth factor (TGF)-β, interferon (IFN)-γ and
soluble IL-2-receptor, although significant heterogeneity was observed
across the different studies (Miller et al., 2011). This may be due to
the small sample size, differences in inclusion and exclusion criteria,
Table 2
Demographic details of patients used for investigating drug effects. Patients were
assessed before (T0) and after (T6) 6 week treatment with different antipsychotics
(ola = olanzapine; quet = quetiapine; risp = risperidone; mix = mix of different
antipsychotics).
Number 32
Treatment (ola/quet/risp/mix) 7/7/9/9
Gender (M/F) 22/10
Age 31.2 ± 10.5
BMI T0 24.0 ± 4.4
BMI T6 24.7 ± 3.9⁎⁎
Smoking (Y/N) 23/9
Cannabis (Y/N) 9/23
Antipsychotic-naïve at T0 32
PANSS positive score T0 21.5 ± 6.5
PANSS negative score T0 18.3 ± 8.9
PANSS general psychopathology score T0 42.4 ± 12.1
PANSS positive score T6 11.7 ± 3.9⁎⁎⁎
PANSS negative score T6 14.2 ± 6.5⁎⁎
PANSS general psychopathology score T6 28.1 ± 8.6⁎⁎⁎
M/F = male/female, BMI = body mass index, Y/N = yes/no, na = not available. Values
are shown as mean ± sd.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001 (Wilcoxon signed-rank test).
24 L. de Witte et al. / Schizophrenia Research 154 (2014) 23–29the use of diverse and non-standardised assay platforms, the sporadic
presence of inflammatory or metabolic co-morbidities, and the large
variability of serum cytokine levels within the normal human popula-
tion (O'Connor et al., 2009). Moreover, peripheral inflammatory
markers can be affected by confounding factors such as age, gender,
smoking, weight and anti-psychotic medication (Park et al., 2005;
Zhang et al., 2008; Miller et al., 2011). Therefore, larger sample num-
bers, stringent inclusion and exclusion criteria, and control of confound-
ing factors are needed to draw reliable conclusions.
With this in mind, we have used a multiplex immunoassay to
measure the levels of 9 cytokines in serum of antipsychotic-naïve
first-episode schizophrenia patients and controls matched for age and
gender. We also attempted to control for body mass index (BMI) and
smoking, although this information was not available for all subjects.
The main aim was to assess the reproducibility of cytokine alterations
across independent cohorts to gain further insight into the role of
these molecules in the aetiology of schizophrenia. In addition, we also
carried out a pilot study to investigate cytokine changes in a subgroup
of these patients who were treated with antipsychotics for 6 weeks.
2. Material and methods
2.1. Clinical samples
First onset and antipsychotic-naïve schizophrenia patients are diffi-
cult to obtain since annual recruitment rates range from 10 to 15 sub-
jects for most clinical centres. We recruited subjects in collaboration
with three centres in Germany and one in TheNetherlands over a period
of 10 years (Table 1). Cohort 1 was from the Department of Psychiatry,
University of Cologne. Cohort 2 was recruited at the Department of
Psychiatry, University of Muenster. Cohorts 3 and 5 were from the
Department of Psychiatry, University of Magdeburg and cohort 4 was
from the ErasmusMedical Centre in The Netherlands. A subgroup of pa-
tients (n= 32; Table 2) from cohort 3 was used in follow-up studies to
investigate antipsychotic treatment effects. The respective institutional
ethical committees approved the study protocols and written informed
consent was given by all participants. All studies were conducted ac-
cording to theDeclaration of Helsinki. Diagnoseswere carried out by ex-
perienced psychiatrists using the Diagnostic and Statistical Manual of
Mental Disorders-IV (DSM-IV) criteria and patients were assessed for
psychopathology using the Positive and Negative Syndrome Scale
(PANSS) (Kay et al., 1987). All clinical tests were performed according
to Good Clinical Practice Guidelines. Healthy controls were recruited
from the same hospitals and associated universities and matched theTable 1
Demographic details of patients from the analysed cohorts.
Cohort 1 2 3
Centre Cologne, Germany Muenster, Germany Magdeb
N 130 92 183
Patients n 71 46 33
Controls n 59 46 150
Patients (M/F) 42/29 35/11 22/11
Controls (M/F) 31/28 35/11 79/71
Patients age 31 ± 10 27 ± 9 31 ± 1
Controls age 30 ± 8 27 ± 9 36 ± 1
Patients BMI 24 ± 5 22 ± 2 26 ± 5
Controls BMI 23 ± 4 na 24 ± 4
Patients tobacco (Y/N/na) 25/23/23 16/26/4 24/9/0⁎
Controls tobacco (Y/N/na) 25/34/0 na 41/109
Patients cannabis (Y/N/na) 33/22/16 15/27/4 9/24/0
Controls cannabis (Y/N/na) 31/25/3 na 2/148/0
Antipsychotic-naïve patients All All All
PANSS positive item score 23 ± 6 18 ± 7 21 ± 6
PANSS negative item score 23 ± 8 18 ± 7 19 ± 9
Sample storage time (years) 6.9 ± 2.6 na na
M/F = male/female, BMI = body mass index, Y/N = yes/no (based on interview), na = not a
⁎ p b 0.05 (Mann–Whitney test).respective patient populations for age, gender and body mass index
(BMI). Patients and controls with a family history of mental disease or
other serious medical conditions such as type II diabetes mellitus,
hypertension, cardiovascular or autoimmune diseases were excluded
from the study. The study protocol, clinical samples and test methods
were carried out in compliance with the Standards for Reporting of
Diagnostic Accuracy (STARD) initiative (Bossuyt and Reitsma, 2003).
2.2. Sample preparation
Blood samples were collected in the morning into S-Monovette
7.5 mL serum tubes (Sarstedt, Numbrecht, Germany). The serum was
prepared according to standard protocols by leaving the samples at
room temperature for 2 h to allow clotting, followed by centrifugation
at 4000 g for 5 min to remove clotted cells and other debris. The
resulting supernatants were stored at −80 °C in Lo-Bind Eppendorf
tubes (Hamburg, Germany) prior to analysis.
2.3. Multiplexed immunoassay analyses
The levels of 21 serumcytokinesweremeasured using aHumanMAP
immunoassay platform as described previously (Schwarz et al., 2010).4 5 Total
urg, Germany Rotterdam, Netherlands Magdeburg, Germany –
54 71 530
14 16 180
40 55 350
11/3 8/8 118/62
33/7 28/27 206/144
0⁎ 24 ± 7 35 ± 11 30 ± 10
0 27 ± 4 34 ± 10 32 ± 10
na 22 ± 3 na
na 23 ± 3 na
10/4/0 6/9/1 81/71/28
/0 na 12/42/1 na
8/6/0 0/15/1 65/94/21
na 0/55/0 na
All All All
na 19 ± 8 na
na 16 ± 4 na
2.5 ± 1.1 na na
vailable. Values are shown as mean ± sd.
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nological (Ottervald et al., 2010; Wagner et al., 2012) and psychiatric
(Domenici et al., 2010; Schwarz et al., 2010) studies for identification
of biomarker candidates. The assays were performed in a Clinical Labo-
ratory Improvement Amendments-certified laboratory at Myriad-RBM
(Austin, TX, USA). In brief, assays were calibrated and absolute protein
concentrations were determined using duplicate 8-points standard an-
tigen curves. Assay performance was verified using quality control
serum samples.
2.4. Statistical analyses
Assays for 9 cytokines [interferon (IFN)-γ, interleukin (IL)-1α,
IL-1RA, IL-5, IL-10, IL-12p40, IL-15, IL-18 and tumour necrosis factor
(TNF)-α] fulfilled the following strict inclusion criteria and were there-
fore included in the study: 1)measurement in all 5 cohorts, 2) only one
cohort withmore than 80%missing data allowed and 3) did not show a
significant correlation with sample storage time. To account for missing
values in the measurement of specific analytes, readings below the
lower limit of quantitation were replaced with half the minimum
value. Analysis of covariance (ANCOVA) indicated that the levels of
most cytokines varied significantly across the cohorts (p value for the
group ∗ cohort interaction b 0.05). Therefore, each cohort was analysed
for cytokine alterations individually.
The application of Shapiro–Wilk tests indicated that none of the
measured analyte values were normally distributed (p b 0.05). There-
fore, Cliff's delta was chosen as a non-parametric estimate of effect size
and calculated for each cohort (Cliff, 1993). To obtain an overall effect
size, the estimates determined for individual cohorts were combinedFig. 1.Non-parametric meta-analysis of nine cytokines across five clinical cohorts. Horizontal lin
for individual cohorts. Diamonds represent the overall effect size estimates and their CIs. The fi
[missing (%)].without weighting. Unweighted Cliff's delta has been shown to outper-
form parametric effect size estimates such as Hedge's g and Cohen's d in
terms of bias under non-normality and variance heterogeneity condi-
tions (Kromrey et al., 2005). This approach minimised any strong influ-
ence of individual cohorts on the overall effect size,which could give rise
to centre-specific findings. Confidence intervals for the overall Cliff's
delta estimates were determined using the adjusted bootstrap percen-
tile interval (bias corrected and accelerated, BCa) (Efron, 1987). This
method finds approximate confidence intervals based on the percentiles
of the bootstrap distribution derived from re-sampling the set of effect
sizes 5000 times determined from all cohorts. For assessment of the
changes in cytokine levels following antipsychotic treatment, non-
parametricWilcoxon signed-rank tests were applied. Spearman correla-
tion testing was also performed to determine if any analyte showed a
significant correlation with symptom improvement (ΔPANSS). All anal-
yses were carried out using the free software package R (http://cran.r-
project.org/) and GraphPad Prism.
3. Results
3.1. Patient characteristics
The serum samples were obtained from 180 first-episode
antipsychotic-naïve schizophrenia patients and 350 healthy controls
matched for age and gender (Table 1). Patients and controls were also
matched for BMI and smoking in cases where this information was
available. As an exception, cohort 3 showed significant differences in
the age of patients and the distribution of smokers in relation to con-
trols. The patients in all cohorts had high average scores for PANSSes indicate 95% confidence intervals (CI) and black circles indicate the average effect sizes
gure also indicates the percentage of values outside the linear range of the assay system
Table 3
Changes in cytokine levels following 6 week treatment with atypical antipsychotics. Reproducible significant findings are shaded.
Cytokine
All patients
(n = 32)
Quetiapine
(n = 7)
Mix of
antipsychotics
(n = 9)
Risperidone
(n = 9)
Olanzapine
(n = 7)
RC p value RC p value RC p value RC p value RC p value
IFN–γ 0.99 1.000 1.10 0.553 1.40 0.527 0.95 0.752 0.50 0.219
IL–1α 0.91 0.299 1.00 1.000 1.05 0.820 0.82 0.203 0.85 0.578
IL–1–RA 0.76 0.005 0.82 0.141 1.23 0.820 0.53 0.035 0.64 0.047
IL–5 0.95 0.510 1.09 0.578 0.86 0.353 0.74 0.050 1.26 0.352
IL–10 0.86 0.059 0.91 0.834 1.02 0.933 0.79 0.042 0.73 0.036
IL–12p40 0.87 0.223 1.11 0.834 1.02 0.933 0.53 0.021 1.10 0.578
IL–15 0.94 0.495 0.76 0.469 1.15 0.575 0.93 0.800 0.88 0.675
IL–18 1.01 0.666 1.17 0.297 1.14 0.374 0.84 0.014 0.94 0.469
TNF–α 1.28 0.070 1.68 0.059 0.83 0.529 1.08 0.800 2.16 0.100
RC = ratio change; p values were calculated with Wilcoxon signed-rank tests.
26 L. de Witte et al. / Schizophrenia Research 154 (2014) 23–29positive and negative scores andwere antipsychotic-naïve at the timeof
blood collection.
3.2. Cytokine alterations in schizophrenia
The serum concentrations of 9 cytokines were measured by
multiplexed immunoassay analysis. This showed that the levels of
these cytokines were not distributed uniformly across the cohorts.
Since the distributions of age, gender, BMI and smoking were not signif-
icantly different, it is likely that other confounding factors which had not
been controlled might have affected the results. To account for this pos-
sibility, we performed a non-parametric meta-analysis to determine theFig. 2. Significant changes following6week treatmentwith atypical antipsychotics. Scattergram
(a, c) and risperidone (b, d). Quetiapine andmixture of antipsychotics did not cause significant ereproducibility of cytokine alterations across the 5 cohorts. This showed
that 3 analytes (IL-1RA, IL-10 and IL-15) were reproducibly increased in
first-onset schizophrenia patients compared to controls (Fig. 1c, e and g).
Themost robust change was observed for IL-10 with average Cliff's delta
reading of 0.36 and only 2% missing values.
Secondary analyses revealed that levels of IL-18 were significantly
higher in smoking patients from cohort 3 (1.33 fold change, p =0.017)
and cohort 5 (3.91 fold change, p = 0.008) when compared to non-
smoking patients. However, these effectswere not reproducible in the re-
maining cohorts. In addition, no reproducible effects were observed with
cannabis use or BMI, although this analysis was limited to only those pa-
tients for whom data on smoking, cannabis use and BMI was available.s show changes in IL-1RA (a–b) and IL-10 (c–d) levels following treatmentwith olanzapine
ffects on IL-1RA and IL-10 levels. p valueswere calculatedwithWilcoxon signed-rank tests.
Table 4
Univariate correlation analysis showing relationship between IL-1RA and IL-10 levels (initial, T0, and change frombaseline toweek 6,Δ) and clinical outcomes. The table shows Spearman's
correlation coefficients rho and corresponding p values (in brackets). Significant correlations are shaded.
ΔPANSS 
positive
ΔPANSS 
negative
ΔPANSS  
general
ΔPANSS    
total
ΔBMI
IL–1RA T0 0.12 (0.519) 0.04 (0.812) 0.10 (0.572) 0.10 (0.575) 0.17 (0.365)
ΔIL–1RA 0.22 (0.227) 0.15 (0.410) 0.29 (0.110) 0.25 (0.164) –0.07 (0.711)
IL–10 T0 0.07 (0.711) 0.11 (0.558) 0.04 (0.807) 0.04 (0.821) –0.06 (0.756)
ΔIL–10 0.30 (0.089) 0.41 (0.018) 0.37 (0.038) 0.45 (0.009) –0.26 (0.142)
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We also carried out multiplex immunoassay analysis of serum from
32patients in cohort 3 after 6 weeks of treatmentwith atypical antipsy-
chotics. The treatment resulted in significant decreases in PANSS posi-
tive, negative and general scores and an average increase in BMI
(Table 2). The immunoassay profiling analysis showed that IL-1RA and
IL-10, which were both increased in the first onset patients, were now
decreased in at least two of the antipsychotic treatment groups
(Table 3). Both molecules showed significant decrease following treat-
ment with risperidone and olanzapine (Fig. 2). Furthermore, Spearman
correlation testing showed that the changes in IL-10 levels were signif-
icantly correlated with symptom improvement (ΔPANSS) for negative,
general and total scores (Table 4). Neither IL-1RA nor IL-10 showed a
correlation with BMI which increased moderately (24.0 to 24.7) after
the 6 week treatment period.4. Discussion
This is thefirstmeta-analysis of cytokine changes infirst-onset drug-
naïve schizophrenia patients compared to well-matched healthy con-
trols across multiple clinical cohorts. All participants underwent exten-
sive clinical assessment, and the samples were processed according to
strict standard operating procedures. To achieve maximum coherence,
sera from different cohorts were analysed with a robust HumanMAP
immunoassay platform in a Clinical Laboratory Improvement Amend-
ments (CLIA)-certified laboratory at Myriad-RBM Inc. (Austin, Texas).
This showed that IL-1RA, IL-10 and IL-15 levels were consistently in-
creased in first onset patients compared to controls throughout the co-
horts. Furthermore,we demonstrated that the levels of IL-1RA and IL-10
were decreased after 6 weeks treatment of 32 patientswith atypical an-
tipsychotics and the change in IL-10 levels was correlated with symp-
tom improvement. The strength of the present study was the high
number of antipsychotic-naïve patients (n = 180) and controls (n =
350) that were matched for potential confounding factors such as age,
gender, BMI and smoking, and the use of a standardised assay platform.
A major consideration of this study was the heterogeneity of
reported serum cytokine changes in schizophrenia. In line with this,
we found that even after excluding subjects with co-morbidities and
matching for potential confounding factors, cytokine variation was
still apparent across the cohorts. Therefore, this variationmay bedepen-
dent on other factors which have not been considered in our and other
studies. In ameta-analysis carried out byMiller et al., increased levels of
the pro-inflammatory cytokines IL-12, TNF-α and IFN-γ were found in
antipsychotic-naïve first-episode patients (Miller et al., 2011), although
we found no changes in the same molecules. However, these analytes
had high percentages of missing values in our study (17% to 45%)
which could have biased our effect size estimates. Another possible ex-
planation for this discrepancy might be the inclusion of data from non-
standardised assays or the potential presence of confounding factors in
meta-analysis described above. Based on our secondary analyses, it isunlikely that the differences were caused by smoking status, cannabis
use or BMI. However, other factors, such as differences in the levels of
physical exercise, socioeconomic status, psychosocial stress, race, or
treatment regimes in different countries, have not been controlled for
in the current investigation or virtually all previous studies.
The cytokines IL-1RA and IL-10 have anti-inflammatory functions,
whereas IL-15 is categorised as pro-inflammatory cytokines. Therefore
the finding that both sets of molecules were increased in first onset
schizophrenia patients suggests a combination of increases in pro- and
anti-inflammatory pathways. This contrasts with some studies which
have identified mainly pro-inflammatory changes in first onset schizo-
phrenia patients (Miller et al., 2011), although it is consistent with
others which have shown mixed responses as we have found here
(Maes et al., 2002; Kunz et al., 2011; Schwarz et al., 2012).
Although we selected first-episode antipsychotic-naïve patients for
this study, it still remains to be determined whether the altered cyto-
kine levels are a cause or consequence of the disease process. Interest-
ingly, a polymorphism in the IL-10 gene (IL10) promoter region that
leads to higher production of IL-10 as well as polymorphisms in the
IL-1RA gene (IL1RN) has been associated with genetic susceptibility to
schizophrenia (Bocchio et al., 2002; Zanardini et al., 2003; Kim et al.,
2004). These genetic studies suggest that IL-10 and IL-1RA may have a
causal role in schizophrenia pathogenesis. Moreover, it is now widely
accepted that peripheral immune alterations can modulate brain func-
tion. For example, peripheral infections, inflammatory responses, or
injection with pro-inflammatory cytokines such as IFN-α can lead to al-
tered brain and behavioural responses (Dantzer, 2004). Furthermore,
animal studies have shown that peripheral injection with specific cyto-
kines can lead to either neuroprotection or neurotoxicity, depending on
the class of molecule administered (Barkhudaryan and Dunn, 1999).
One study suggested that peripheral IL-15 may induce depression-like
behaviour and others reported an increase of IL-15 in schizophrenia
(Domenici et al., 2010; Wu et al., 2011).
The finding that IL-1RA and IL-10 levels were decreased after treat-
ment with atypical antipsychotics suggests that these molecules might
be involved in the therapeutic response to antipsychotic treatment. In-
deed, reduction in IL-10 was significantly correlated with symptom im-
provement. As thesemolecules are anti-inflammatory, a reduction could
signify that antipsychotics promote certain inflammatory responses.
This is consistent with the findings that side-effects by atypical antipsy-
chotics are associated with increased inflammatory markers (Dieset
et al., 2012; Na et al., 2012). It has previously been shown that antipsy-
chotics can directly modulate response of immune cells such as macro-
phages and microglia (Kato et al., 2011; Chen et al., 2013). Moreover,
different classes of neurotransmitter receptors are expressed by immune
cells and the appropriate neurotransmitters can alter cytokine responses
of these cells (Idova et al., 2012; Lee, 2013). However, more complex
mechanisms may be involved in the observed cytokine responses, such
as the potential effect of decreased psychological stress on serum cyto-
kine levels after antipsychotic treatment (Calcagni and Elenkov, 2006).
One limitation of the current study was the small number of cyto-
kines investigated. This can lead to a potential bias. This procedure
28 L. de Witte et al. / Schizophrenia Research 154 (2014) 23–29was based on the commercial availability of a multiplexed immunoas-
say platform and did not specifically target all key regulators of
immune- and inflammation related pathways. Future studies should in-
vestigate a broader range of molecules and include those from other
molecular classes such as growth factors or hormones. Another poten-
tial limitation comes from the fact that samples were not necessarily
collected from participants under fasting conditions. This could be
important as previous studies have shown that cytokine levels can fluc-
tuate according to dietary intake (Blok et al., 1996). Further clinical
and pre-clinical studies are required to unravel the role of cytokine
alterations in schizophrenia and find strategies for better treatment
approaches. Indeed, the first trials investigating therapies for schizo-
phrenia targeting the immune system have shown promising results
(Sommer et al., 2011). Evaluation of the cytokine alterations before
and during treatment in these trials may help to target the relevant
patient population by stratification based on these signatures, predict
treatment responses to current medications and identify potential
novel immunomodulatory approaches for adjunctive treatments with
traditional antipsychotics.
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